Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Transdermal Clonidine (Vistanex vs Oppanol)
NCT02096744Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of clonidine in hypertension (HTN) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve 0-168h and Average Concentration. Started Mar 2014; status: completed.
02
Drugs
clonidine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02096744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096744.